Veterinary Services MarketSize, Share & Industry Analysis, 2026-2034By Animal TypeBy Service TypeBy Delivery ChannelBy Practice OwnershipBy Payment Mode

Veterinary services cover the diagnostic, preventive, medical and surgical care that a licensed practice or mobile provider delivers to companion and production animals, spanning routine wellness exams, vaccination and parasite control, diagnostic imaging and laboratory testing, and surgical or emergency treatment. Buyers range from individual pet owners and breeders to commercial livestock operations, dairies and poultry integrators that contract ongoing herd or flock health management. Care is delivered through fixed hospitals and clinics, retail or commercial facilities, and outdoor or ambulatory visits where a provider travels to the animal instead of the animal being brought in.

Between 2025 and 2034 the global veterinary services market moves from USD 131.43 billion to USD 291.71 billion, compounding at 9.35% a year. Fifteen years are covered in all, taking in USD 91.55 billion in 2020, USD 122.26 billion in 2024, USD 142.73 billion in 2026 and USD 206.65 billion in 2030.

57% of 2025 revenue sits in Companion Animal, worth USD 74.92 billion and rising to USD 180.86 billion at 62% by 2034, the largest animal type line in both years. Growth is fastest in Companion Animal at 10.37% and slowest in Production Animal at 7.58%. The lines gaining share are Companion Animal. Production Animal and Others lose share without losing revenue.

The service type split puts Physical health monitoring first, at USD 49.94 billion and 38% of revenue in 2025, rising to USD 99.18 billion and 34% in 2034. Diagnostic tests and imaging grows faster at 11.65% against 7.91%, moving from 28% of revenue to 34% by 2034. It cuts the same total as the animal type axis from a different commercial angle, so revenue does not add across the two.

USD 44.69 billion of 2025 revenue is generated in North America, 34% of the global total and the largest regional share; it reaches USD 87.51 billion by 2034. Europe is next at 26% and USD 34.17 billion, and Middle East and Africa last at 7%. Because Asia Pacific, Latin America and Middle East and Africa take share, the revenue added by 2034 concentrates instead of spreading across all five regions.

Behind these figures sit five regions, three animal type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is triangulated from published sources and category proxies, with no independently sourced count behind it, and the same applies to the segment, regional and country breakdowns drawn from it.

• The global veterinary services market moves from USD 91.55 billion in 2020 to USD 131.43 billion in 2025 and USD 291.71 billion by 2034, the forecast period compounding at 9.35% a year.
• The largest line by animal type is Companion Animal, worth USD 74.92 billion and 57% of revenue in 2025, rising to USD 180.86 billion and 62% by 2034.
• The bull case puts 2034 revenue at USD 309.21 billion and the bear case at USD 271.29 billion, either side of the USD 291.71 billion base case, each with its own stated assumption in the full report.
• The largest region is North America, generating USD 44.69 billion in 2025 (34% of the global total) and USD 87.51 billion by 2034, ahead of Europe at 26%.
• The United States accounts for 85% of North America in the base year, worth USD 37.99 billion in 2025 and reaching USD 74.38 billion by 2034, the worked country example carried through that region's chapters.
• Fifteen years are reported, 2020 to 2034 with 2025 as the base: revenue, share and growth rate per line, per axis and per region, not as a single blended series.

The global veterinary services market is shaped over 2026-2034 by three measurable movements: a change in the animal type mix, a shift in where revenue sits geographically, and the 9.35% rate carrying the total.

Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.

Companion Animal outpaces Production Animal. Between 2026 and 2034, 10.37% growth in Companion Animal against 7.58% in Production Animal pulls the animal type mix apart. Over the forecast period that moves Companion Animal from 57% of revenue to 62%, and Production Animal from 37% to 32%. Revenue rises on both sides; USD 74.92 billion to USD 180.86 billion and USD 48.63 billion to USD 93.35 billion respectively, so this is a change in composition, not a contraction, and one forecast window is long enough for it to matter.

Regional weight shifts toward Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 24% of revenue in 2025 to 30% in 2034, worth USD 31.54 billion rising to USD 87.51 billion; Latin America moves from 9% of revenue in 2025 to 9.5% in 2034, worth USD 11.83 billion rising to USD 27.71 billion; Middle East and Africa moves from 7% of revenue in 2025 to 7.5% in 2034, worth USD 9.2 billion rising to USD 21.88 billion. Against that, North America at 34% moving to 30%, Europe at 26% moving to 23%, a fall in share, not in revenue. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

The series never breaks trajectory. Year by year the total runs USD 91.55 billion in 2020, USD 122.26 billion in 2024, USD 131.43 billion in 2025, USD 142.73 billion in 2026, USD 206.65 billion in 2030 and USD 291.71 billion in 2034. No year breaks the trajectory, and the 9.35% forecast rate compares with 7.51% recorded over 2020-2025, a continuation, not an inflection. A plan built on this market is therefore a plan about capturing a share of steady expansion, which is decided on the animal type and regional axes, not by the headline rate.

Companion Animal carries the market's growth rate

Separate the 9.35% into its parts and three show up: an already-large base compounding, the animal type mix moving toward its faster lines, and regional growth landing unevenly.

Downside case: USD 271.29 billion by 2034, against USD 291.71 billion in the base case

Upside case: USD 309.21 billion by 2034

Concentration on the animal type axis

North America holds 34% of the global veterinary services market in 2025, worth USD 44.69 billion and reaches USD 87.51 billion by 2034. It is a leading region on this axis, first by revenue throughout the period.

By 2034 the share stands at 30%, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

The animal type mix reported at global level applies here, with Companion Animal the largest line at 57% of 2025 revenue and Companion Animal the fastest-growing at 10.37%. The full report breaks North America out along every axis and by country.

The largest single market in North America is the United States, at USD 37.99 billion in 2025 and USD 74.38 billion in 2034. 85% of the region in 2025 means the regional figures are, in practice, a view of this market with others attached. Set against USD 44.69 billion and USD 87.51 billion for the region, it is why this market, and not a smaller one, is the one reported in full.

the United States buys along the same lines as the market globally; Companion Animal first at 57% of 2025 revenue and 62% in 2034, Companion Animal fastest at 10.37% on a share moving from 57% to 62%. Because the country carries 85% of North America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The United States carries its own animal type breakdown in the full report.

In the United States, the practice of veterinary medicine is licensed and disciplined at the state level under each state's veterinary practice act, administered by a state veterinary medical board that examines candidates, issues licenses to veterinarians and credentialed veterinary technicians, and sets standards of care and continuing education. Veterinary colleges are accredited through the American Veterinary Medical Association's Council on Education, and hospitals may seek voluntary facility accreditation through bodies such as the American Animal Hospital Association. Drugs, biologics, and devices used in delivering these services fall under the Food and Drug Administration's Center for Veterinary Medicine and the Department of Agriculture, so a provider's supply chain answers to federal rules even though the license to practice remains a state matter.

In the United States the field is Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL. Companion Animal is both the largest line, at 57% of 2025 revenue, and the fastest-growing at 10.37%. The full report covers country-level positioning and shares company by company; this summary does not.

5.1% of global revenue is generated in Canada; USD 6.7 billion in 2025, reaching USD 13.13 billion in 2034, and 15% of North America.

26% of the global veterinary services market sits in Europe in 2025, worth USD 34.17 billion and reaches USD 67.09 billion by 2034. It is a leading region on this axis, second by revenue throughout the period.

23% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.

The animal type mix reported at global level applies here, with Companion Animal the largest line at 57% of 2025 revenue and Companion Animal the fastest-growing at 10.37%. Revenue for Europe is broken out by every segmentation axis and by country in the full report.

27% of Europe's base-year revenue comes from Germany; USD 9.23 billion, rising to USD 18.11 billion by 2034. At 27% of the region in 2025 it leads, but a majority of Europe's revenue is generated in other markets. Against regional totals of USD 34.17 billion in 2025 and USD 67.09 billion in 2034, it is the country the full report breaks out in detail.

Composition here matches the global split: the largest line is Companion Animal at 57% of 2025 revenue, easing to 62% by 2034, and the fastest is Companion Animal at 10.37%, from 57% to 62%. Its 27% weight in Europe means those movements carry straight into the regional totals. Revenue by animal type for Germany is reported separately in the full report.

Veterinary services in Germany operate under the Federal Veterinary Act, which requires practitioners to pass a state examination and register with the veterinary chamber of the federal state in which they practice; these chambers, coordinated nationally through the Bundestierärztekammer, set professional conduct rules and continuing education obligations. Animal health surveillance and disease control sit with the Friedrich-Loeffler-Institut and the federal and state agriculture ministries, while veterinary medicinal products used in clinics are governed by the German Medicines Act alongside the EU framework for veterinary medicines. A clinic or mobile practice must combine chamber registration for its veterinarians with compliance on the medicines it dispenses and administers.

The suppliers tracked in this study (Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL) compete in Germany across the animal type lines above. Companion Animal is both the largest line, at 57% of 2025 revenue, and the fastest-growing at 10.37%. A supplier weighted toward Europe is competing over a base of USD 34.17 billion in 2025 reaching USD 67.09 billion by 2034, 26% of global revenue at the start of that period.

5.2% of global revenue is generated in France; USD 6.83 billion in 2025, reaching USD 13.42 billion in 2034, and 20% of Europe.

4.94% of global revenue is generated in the United Kingdom; USD 6.49 billion in 2025, reaching USD 12.75 billion in 2034, and 19% of Europe.

In Asia Pacific, 24% of global revenue puts 2025 at USD 31.54 billion with USD 87.51 billion projected for 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

Its share rises to 30% over the forecast period, on growth above the market's own 9.35%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Companion Animal leads here as it does globally, at 57% of 2025 revenue, and Companion Animal again grows fastest at 10.37%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.

32% of Asia Pacific's base-year revenue comes from China; USD 10.09 billion, rising to USD 28 billion by 2034. At 32% of the region in 2025 it leads, but a majority of Asia Pacific's revenue is generated in other markets. Regional revenue of USD 31.54 billion in 2025 and USD 87.51 billion in 2034 sits around it, and it is the country used wherever the full report cuts a figure by geography.

Demand in China follows the animal type mix reported at global level: Companion Animal is the largest line at 57% of 2025 revenue, moving to 62% by 2034, while Companion Animal grows fastest at 10.37% and takes its share from 57% to 62%. Since 32% of Asia Pacific's revenue is generated here, the regional numbers inherit this market's mix instead of smoothing it out. China carries its own animal type breakdown in the full report.

China's Ministry of Agriculture and Rural Affairs sets the national framework for veterinary practice under regulations governing veterinary practitioners, requiring individuals to pass a national qualification examination and register before treating animals or operating a clinic. Provincial and municipal agriculture bureaus license veterinary hospitals and clinics locally, inspect premises, and enforce hygiene and biosecurity requirements tied to the country's animal epidemic prevention rules. Veterinary drugs and biologics dispensed during treatment are separately controlled through the national veterinary drug administration system, with clinics expected to source only approved products and keep records supporting traceability back to a licensed supplier or manufacturer.

Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL are the suppliers covered in China. Companion Animal is both the largest line, at 57% of 2025 revenue, and the fastest-growing at 10.37%. Weighting toward Asia Pacific means competing for 24% of 2025 global revenue, a base of USD 31.54 billion moving to USD 87.51 billion across the forecast period.

Japan is sized at USD 6.31 billion in 2025, rising to USD 17.5 billion by 2034; 4.8% of global revenue and 20% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

3.6% of global revenue is generated in India; USD 4.73 billion in 2025, reaching USD 13.13 billion in 2034, and 15% of Asia Pacific.

USD 11.83 billion of 2025 revenue is generated in Latin America, 9% of the global veterinary services market with USD 27.71 billion projected for 2034. By revenue it sits fourth across the study, and the ranking does not change between 2025 and 2034.

Its share rises to 9.5% over the forecast period, so the region grows faster than the market's 9.35% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Companion Animal leads here as it does globally, at 57% of 2025 revenue, and Companion Animal again grows fastest at 10.37%. Latin America is reported axis by axis and country by country in the full study.

USD 5.32 billion of Latin America's 2025 revenue is generated in Brazil, the region's largest market, reaching USD 12.47 billion by 2034. It accounts for 45% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 11.83 billion in 2025 and USD 27.71 billion in 2034, it is the country the full report breaks out in detail.

The animal type pattern in Brazil is the global one: 57% of 2025 revenue in Companion Animal, 62% by 2034, against 10.37% growth in Companion Animal taking it from 57% to 62%. Because the country carries 45% of Latin America, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Revenue by animal type for Brazil is reported separately in the full report.

In Brazil, veterinary practice is licensed through the Federal Council of Veterinary Medicine and its regional councils, which register veterinarians, accredit veterinary establishments, and enforce a code of professional ethics covering clinical conduct and advertising. The Ministry of Agriculture, Livestock and Supply sets animal health policy and oversees the products and biologics used within clinical settings, working alongside state-level agricultural defense agencies on disease notification and control. A veterinary clinic or hospital must hold current registration with its regional council, employ only licensed veterinarians, and maintain facilities that meet the council's standards for hygiene, equipment, and record-keeping before it can lawfully treat animals or advertise its services.

The suppliers tracked in this study (Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL) compete in Brazil across the animal type lines above. Companion Animal is both the largest line, at 57% of 2025 revenue, and the fastest-growing at 10.37%. The commercial size of that position is USD 11.83 billion in 2025 and USD 27.71 billion by 2034, 9% of the global total in the base year.

2.25% of global revenue is generated in Mexico; USD 2.96 billion in 2025, reaching USD 6.93 billion in 2034, and 25% of Latin America.

USD 9.2 billion of 2025 revenue is generated in Middle East and Africa, 7% of the global veterinary services market and reaches USD 21.88 billion by 2034. Among the five regions it ranks fifth by revenue in both years.

By 2034 the share has moved up to 7.5%, so the region grows faster than the market's 9.35% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: Companion Animal largest at 57% of 2025 revenue, Companion Animal fastest at 10.37%. Per-axis and per-country detail for Middle East and Africa sits in the full report.

USD 2.02 billion of Middle East and Africa's 2025 revenue is generated in Saudi Arabia, the region's largest market, reaching USD 4.81 billion by 2034. At 22% of the region in 2025 it leads, but a majority of Middle East and Africa's revenue is generated in other markets. The region itself runs USD 9.2 billion to USD 21.88 billion over the same period, and this is the market carrying the country-level detail in the full report.

Saudi Arabia buys along the same lines as the market globally; Companion Animal first at 57% of 2025 revenue and 62% in 2034, Companion Animal fastest at 10.37% on a share moving from 57% to 62%. Because the country carries 22% of Middle East and Africa, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. Per-animal type revenue for Saudi Arabia appears on its own in the full report.

Veterinary services in Saudi Arabia fall under the Ministry of Environment, Water and Agriculture, which licenses veterinarians and veterinary clinics, sets facility standards, and coordinates animal health and disease control programs nationally. The Saudi Food and Drug Authority separately governs the veterinary medicines and biologics that a clinic dispenses or administers, requiring registration of products before they reach clinical use. A provider seeking to open a clinic or hospital must obtain ministry approval for the premises and staff qualifications in addition to complying with product-level registration, so licensure runs on two parallel tracks: one for the premises and staff, another for each product placed into clinical use.

The suppliers tracked in this study (Merck Animal Health, Ceva Sante Animale, Vetoquinol S.A., Zoetis, Boehringer Ingelheim GmbH, Elanco, Nutreco N.V., Virbac, Kindred Biosciences, Inc., Biogenesis Bago, Indian Immunologicals Ltd., Neogen Corp., Hester Biosciences, Phibro Animal Health and Dechra Pharmaceuticals PL) compete in Saudi Arabia across the animal type lines above. One line leads on both counts here: Companion Animal holds 57% of 2025 revenue and compounds fastest at 10.37%. A supplier weighted toward Middle East and Africa is competing over a base of USD 9.2 billion in 2025 reaching USD 21.88 billion by 2034, 7% of global revenue at the start of that period.

Within Middle East and Africa, South Africa accounts for 20% of regional revenue and 1.4% of the global total, worth USD 1.84 billion in 2025 and USD 4.38 billion by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by animal type, service type, delivery channel, practice ownership, payment mode, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.